ALG-055009, Publications Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
Pevifoscorvir-sodium, Publications Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks
ALG-055009, Publications Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
Pevifoscorvir-sodium, Publications A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants
Pevifoscorvir-sodium, Publications Oral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBV
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAg
Preclinical, Publications Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time
Preclinical, Publications CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In Vitro